|Mr. G. Andre Turenne||CEO, Pres & Director||797.68k||N/A||1974|
|Mr. Robert W. Hesslein||Sr. VP & Gen. Counsel||544.4k||N/A||1953|
|Dr. Omar Khwaja M.D., Ph.D.||Chief Medical Officer and Head of R&D||698.59k||N/A||1970|
|Dr. Steven M. Paul M.D.||Exec. Science Advisor & Director||333.09k||N/A||1951|
|Dr. Krystof Bankiewicz M.D., Ph.D.||Founder||N/A||N/A||N/A|
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Voyager Therapeutics, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.